Abstract：
OBJECTIVE: High-grade parotid carcinoma generally has a poor prognosis, and the histological type is mucoepidermoid carcinoma (MEC), salivary duct carcinoma (SDC), carcinoma ex pleomorphic adenoma (CEPA), or adenoid cystic carcinoma (AdCC) in the majority of cases.
METHODS: During the 23-year period from September 1999 to December 2022, 250 patients with parotid carcinoma underwent initial treatment and had the histopathological type of their carcinoma. Retrospective study evaluated 111 MEC, SDC, CEPA, or AdCC cases among 134 patients with high-grade parotid carcinoma. We examined pathological and clinical features and prognosis, evaluated factors associated with recurrence, and performed immunohistological examinations.
RESULTS: Pathological and clinical features and factors associated with recurrence were different for each histological type. The 10-year disease-free survival rates were as follows: MEC, 34.9%; SDC, 22.6%; CEPA, 47.1%; and AdCC, 56.3%. Human epidermal growth factor receptor type-2 and androgen receptor were positive in 48% and 56% of patients with SDC, respectively, 38% and 25% of those with CEPA.
CONCLUSIONS: Each histological type has its own pathological and clinical features, recurrence types, and tumor activities, suggesting that differentiating between high-grade parotid carcinomas according to histological type will improve diagnosis, and thus prognosis.
METHODS: During the 23-year period from September 1999 to December 2022, 250 patients with parotid carcinoma underwent initial treatment and had the histopathological type of their carcinoma. Retrospective study evaluated 111 MEC, SDC, CEPA, or AdCC cases among 134 patients with high-grade parotid carcinoma. We examined pathological and clinical features and prognosis, evaluated factors associated with recurrence, and performed immunohistological examinations.
RESULTS: Pathological and clinical features and factors associated with recurrence were different for each histological type. The 10-year disease-free survival rates were as follows: MEC, 34.9%; SDC, 22.6%; CEPA, 47.1%; and AdCC, 56.3%. Human epidermal growth factor receptor type-2 and androgen receptor were positive in 48% and 56% of patients with SDC, respectively, 38% and 25% of those with CEPA.
CONCLUSIONS: Each histological type has its own pathological and clinical features, recurrence types, and tumor activities, suggesting that differentiating between high-grade parotid carcinomas according to histological type will improve diagnosis, and thus prognosis.
摘要：
目的：高级别腮腺癌通常预后较差，组织学类型是粘液表皮样癌（MEC），涎管癌（SDC），多形性腺瘤（CEPA），或腺样囊性癌（AdCC）在大多数情况下。
方法：在1999年9月至2022年12月的23年期间，250例腮腺癌患者接受了初始治疗，并具有癌的组织病理学类型。回顾性研究评估了111MEC，SDC,CEPA,134例高级别腮腺癌患者中的AdCC病例。我们检查了病理和临床特征以及预后，评估与复发相关的因素，并进行了免疫组织学检查。
结果：每种组织学类型的病理和临床特征以及与复发相关的因素不同。10年无病生存率如下：MEC，34.9%；SDC，22.6%;CEPA,47.1%；和AdCC，56.3%。人表皮生长因子受体2型和雄激素受体在SDC患者中分别为48％和56％，分别,38%和25%的CEPA。
结论：每种组织学类型都有其自身的病理和临床特征，复发类型，和肿瘤活动，提示根据组织学类型区分高级别腮腺癌将改善诊断，从而预后。
方法：在1999年9月至2022年12月的23年期间，250例腮腺癌患者接受了初始治疗，并具有癌的组织病理学类型。回顾性研究评估了111MEC，SDC,CEPA,134例高级别腮腺癌患者中的AdCC病例。我们检查了病理和临床特征以及预后，评估与复发相关的因素，并进行了免疫组织学检查。
结果：每种组织学类型的病理和临床特征以及与复发相关的因素不同。10年无病生存率如下：MEC，34.9%；SDC，22.6%;CEPA,47.1%；和AdCC，56.3%。人表皮生长因子受体2型和雄激素受体在SDC患者中分别为48％和56％，分别,38%和25%的CEPA。
结论：每种组织学类型都有其自身的病理和临床特征，复发类型，和肿瘤活动，提示根据组织学类型区分高级别腮腺癌将改善诊断，从而预后。
